Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. (Q33408501)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

James Chung-Man Ho

25

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

31

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

author name string

Jin Soo Lee

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Sumitra Thongprasert

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Li Zhang

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Guia Ladrera

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Vichien Srimuninnimit

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Virote Sriuranpong

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Jennifer Sandoval-Tan

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Yunzhong Zhu

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Meilin Liao

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Caicun Zhou

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Hongming Pan

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Victor Lee

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Yuh-Min Chen

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Yan Sun

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Benjamin Margono

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Fatima Fuerte

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Gee-Chen Chang

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Kasan Seetalarom

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Jie Wang

21

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Ashley Cheng

22

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Elisna Syahruddin

23

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Xiaoping Qian

24

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Johan Kurnianda

26

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Hsingjin Eugene Liu

27

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Kate Jin

28

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Matt Truman

29

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Ilze Bara

30

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

publication date

17 June 2013

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

777-786

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Optimizing first-line treatment options for patients with advanced NSCLC.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors? - A literature-based meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase III randomized trial of gemcitabine-oxaliplatin versus carboplatin-paclitaxel as first-line therapy in patients with advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970254-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(13)70254-7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23782814%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33408501&oldid=1979087869"